Lung concentrations of a drug are expected to drive the pharmacodynamic response to local inflammation after inhalation delivery, and the only way of determining the efficacious dose has been to measure it directly in animal models. In this study, we present a method to predict efficacious lung doses after inhalation in a rat lipopolysaccharide challenge model from in silico predictions of lung concentration and in vitro measurements only. A quantitative structure-activity relationship (QSAR) model, based on calculated physical properties predicted the partitioning of 34 compounds between lung and plasma. Because it was observed that lung/ plasma partitioning correlated with lung concentration, it was possible to use this relationship to predict lung concentration at a given dose and time point. Based on the pharmacokinetic-pharmacodynamic (PKPD) relationship observed, a minimal free lung concentration relative to potency to drive significant inhibition of neutrophilia was established. By using predicted lung concentrations, measured fraction unbound in plasma, and cellular potency, it was possible to estimate an inhaled lung dose that would be expected to achieve this target exposure. These predictions were made for 23 compounds, which were not part of the original QSAR training set, and all except one were predicted to within 3-fold of their measured values. This novel approach shows that by understanding PKPD relationships and drivers for lung affinity after inhalation dosing, it is possible to estimate in vivo lung doses required for efficacy. This methodology provides a useful screening tool to rank candidate compounds and minimizes the use of extensive animal testing.
Introduction
Inhalation delivery is well established as an approach for targeting drugs into the lung for treating respiratory diseases as well as for systemic delivery of specific agents such as anesthetics. The understanding of lung pharmacokinetic-pharmacodynamic (PKPD) relationships is limited, although it is reasonably hypothesized that local lung concentrations will relate to the efficacy achieved. Better understanding of the factors controlling a PD response after inhalation would improve the speed and quality of drug discovery for respiratory diseases and minimize the use of animals by allowing prediction of efficacious doses from in vitro and in silico parameters.
Inhalation results in drug delivered both to the lung and gut from the same administration and the proportion reaching the lung, in animals or humans, can be unclear, leading to difficulty in understanding the exact dose driving the local lung PD response. A further challenge is to identify the exact local lung concentrations responsible for efficacy in animal models, and this is virtually impossible in humans. Although determining total lung concentrations in animal models is relatively straightforward, relying on such approaches leads to using considerably more animals than are required for traditional plasma pharmacokinetic determination. In addition, because it is believed that free concentrations drive pharmacodynamic responses for classic enzyme and receptor occupancy models, some consideration must be given to free rather than total lung concentrations.
There have been reports of some of the factors controlling lung pharmacokinetics in animal models, such as absorption (Brown and Schanker, 1983; Tronde 2002; Tronde et al., 2003; Horvath et al., 2007) and lung metabolism (Lee et al., 1998; Anttila et al., 2001; Kim et al., 2004) as well as pharmacokinetic modeling of selected compounds or drugs (Jendbro et al., 2001) . However, there is a paucity of reports directly relating lung concentrations to pharmacodynamic responses and factors responsible for driving lung exposure. This article describes use of in vitro data and predicted lung concentrations to estimate the lung dose required for efficacy in a typical animal pharmacodynamic model.
Materials and Methods
Compound Source. All compounds were synthesized by AstraZeneca and represent a range of chemical structures and series. When molecules were chiral, these compounds were prepared as single enantiomers (Ͼ98% enantiomeric purity) unless otherwise stated.
Plasma Protein Binding. Rat plasma protein binding was determined by equilibrium dialysis. Dialysis membranes (molecular weight cutoff of 5000; NBS Biologicals Ltd., Huntingdon, Cambridgeshire, UK) were prepared by soaking in the dialysis buffer (0.1 M phosphate buffer) for a minimum of 1 h. Stock solutions of compounds in dimethyl sulfoxide were prepared and added to the plasma to give a final concentration of 5 M. Mixtures of up to 10 compounds per dialysis cell were dialyzed for 18 h at 37°C, in accordance with established literature methods (Fung et al., 2003; Testa et al., 2006) . The plasma and buffer were analyzed by high-performance liquid chromatography with mass spectrometric detection (HPLC-MS/MS) on a Waters Premier XE triple quadrupole mass spectrometer. A five-point matrix-matched calibration curve was constructed for each compound to determine percent bound. Rat free fraction (percentage) was calculated from (100% Ϫ percent bound). All measurements were made in duplicate.
Cellular Potency (Rat AM pIC 50 ). The cellular potency of the compounds was determined by measuring inhibition of lipopolysaccharide (LPS)-induced TNF-␣ release from the rat alveolar macrophage cell line, NR8383 (original source American Type Culture Collection, Manassas, VA). NR8383 cells were grown in Ham's Nutrient Mixture F12 medium plus 15% FCS at 37°C in humidified 5% CO 2 /95% air. Cells were plated into BioCoat 96-well plates (R&D Systems Europe Ltd., Abingdon, Oxfordshire, UK) at 10 5 /well in Ham's Nutrient Mixture F12 medium plus 5% FCS (Sigma Chemical, Poole, Dorset, UK) and incubated overnight to allow adherence. The next day medium was aspirated from wells and replaced with Ham's Nutrient Mixture F12 plus 5% FCS. Test compounds were added to the adherent macrophages at various concentrations and left to incubate at 37°C for 30 min. The cells were then stimulated with LPS at 37°C. Four hours later, cell-free supernatant was generated by removing the supernatant and centrifuging at 400g for 10 min. Supernatants were stored frozen at Ϫ20°C, and TNF-␣ was quantified using a DuoSet enzyme-linked immunosorbent assay development kit (R&D Systems).
Animals Supply. Male Wistar Han or Sprague-Dawley rats (ϳ250 -450 g; Charles River, Margate, Kent, UK) were used for in vivo pharmacokinetic experiments. Animals were housed under standard conditions in accordance with the Home Office Code of Practice for the Housing and Care of Animals used in Scientific Procedures, with a minimum of 1 week acclimatization after arrival. All animal work was performed in accordance with the Animal (Scientific Procedures) Act of 1986. Rats had free access to pelleted food and potable water other than when dosing or sampling took place. All rats were killed by an intraperitoneal injection of Euthatal (200 mg/ml sodium pentobarbitone; Merial Animal Health Ltd., Harlow, UK).
Pharmacokinetic Experiments. For intravenous administration, two rats per compound were dosed via bolus administration of 1 ml/kg into a prewarmed tail vein, at a dose of 1 mg/kg. All compounds were prepared as a solution in saline, 20% dimethyl acetamide in water, or 0.01 M citrate buffer, pH 3. Serial blood samples were taken from the tail vein or precannulated jugular vein over a 24-h period. For intratracheal dosing, two rats per compound per terminal time point were anesthetized with isoflurane in oxygen then suspended at a 60°angle. Using a laryngoscope to hold the tongue and illuminate the airways, a PennCentury intratracheal aerosolizer (microsprayer) (supplied by EMMS, Bordon, Hants, UK) was placed gently past the epiglottis, via the mouth, into the trachea. Compound was then delivered (1 mg/kg and 1 ml/kg) in 0.1% Tween 80 -0.6% sodium chloride in 0.05 M phosphate buffer, pH 6. Inhalation delivery to rats was as described under Pharmacodynamic Experiments with Direct Measurements of Compound Concentrations.
At appropriate times up to 24 h postdose, serial blood samples were taken from the tail vein or precannulated jugular vein up to the terminal time point. All blood samples were centrifuged for 5 min at approximately 13,000 rpm to produce plasma, which was then stored at approximately Ϫ20°C before sample processing and analysis. At the appropriate terminal time point, rats were terminally anesthetized, and lungs were excised and frozen at approximately Ϫ20°C before sample processing and analysis. The in silico quantitative structure-activity relationship (QSAR) model was developed using the concentrations measured at 6 h postdose from a range of monobasic compounds. Other times points were taken for selected compounds to determine the overall pharmacokinetic profile.
Pharmacodynamic Experiments with Direct Measurements of Compound Concentrations. The anti-inflammatory in vivo potency and efficacy of test compounds was assessed after inhalation delivery in a LPS-induced airway inflammation model in male Wistar Han rats. Animals (n ϭ 15/dose level) were dosed by nose-only exposure to aerosolized compound in a "directed flow" inhalation chamber for 30 min (EMMS). Compounds were administered as aerosolized solutions using a jet nebulizer at 0.5 or 4 h before rats were challenged with LPS (0.1% Tween 80 -0.6% NaCl in 0.05 M phosphate buffer, pH 6). A dose response was investigated by varying the nebulizer concentration of compound. Vehicle controls were also administered in the same way. A positive control, dosed orally at 30 mg/kg 1 h before LPS challenge, was administered in each study.
A 25-mm GF/B filter was attached to a free port on the inhalation tower and connected to a filter pump (calibrated using a mass flow meter; TSI Incorporated, Shoreview, MN). In general, one filter sample was taken throughout the 30-min exposure time to determine the column cloud concentration. The filter sample was collected for 30 min at 0.2 l/min flow rate. LPS (0.5 mg/ml) was administered by inhalation (n ϭ 12/dose level of compound-treated animals) using a whole-body aerosol exposure chamber for 30 min, and rats were killed 4 h later. A tracheotomy was performed, and a cannula was inserted. The airway was then lavaged using 3 ml of sterile Isoton at room temperature. The Isoton was left in the airway for 10 s before being removed and placed in a 15-ml centrifuge tube on ice. This process was repeated two more times, and BAL fluid was placed in a second tube. These animals had a terminal blood sample taken from the dorsal vena cava into 0.5-ml EDTA tubes. The blood sample was centrifuged at 10,000 rpm in a Heraeus Biofuge Fresco centrifuge for 5 min, and plasma was removed and stored as two 50-l aliquots at Ϫ80°C before analysis. The left lobe of the lung was removed from compound-treated animals and cleared of superfluous tissue before storing on ice and then at Ϫ80°C before analysis. These samples provided minimal plasma and lung concentrations achieved in the test animals.
The additional compound-treated animals were culled at the end of the inhalation dosing period. These samples provided maximum plasma and lung concentrations achieved from the same inhalation dosing delivery as from the LPS-treated animals and thus represented relevant concentrations. Culling animals was the only way to acquire lung tissue to measure maximum concentrations. These animals were bled from the tail vein under terminal isoflurane anesthesia and then killed by exsanguination.
Compound measurements from all plasma and lung samples were processed and analyzed as described under Compound Analysis. These data were used to determine the inhaled lung dose as described under Data Analysis.
Compound Analysis. Plasma samples were prepared by adding a known volume to 2 equivalent volumes of methanol and microfuged, and supernatants were spiked with internal standard before analysis by LC-MS/MS as described below. Standards were prepared by spiking known concentrations of compounds into blank rat plasma. These standards were then processed in the same way as the test samples. Lungs were frozen in liquid nitrogen and pulverized using a Covaris tissue pulverizer (KBiosciences, Hoddesdon, Herts, UK). Three times the weight of water was added, and the samples were sonicated for approximately 2 min. Next, twice the volume of methanol was added, and the samples were sonicated again. Finally, the samples were centrifuged, and an aliquot of supernatant was added to a known volume of methanol containing internal standard.
Filters collected from inhalation towers were transferred to a 60-ml amber jar, and 10 ml of acetonitrile-water (50:50, v/v) was added. The mixture was shaken using a shaking table at 100 rpm for 2 h at room temperature. After this time, the solution was filtered through a 0.45-m filter into a suitable container and stored. Immediately before analysis by LC-MS/MS, as described below, samples were diluted in methanol over a range from 1-to 20-fold and spiked into a blank plasma matrix to allow measurement from the plasma standard curve. Dose solutions taken from before and after nebulizing were kept for concentration analysis. Immediately before analysis, these samples were diluted over a range of 1-to 20-fold to allow measurement against a methanolic standard curve.
Samples were analyzed by LC-MS/MS on a Quantum Access triple quadrupole mass spectrometer (Thermo Fisher Scientific, Hemel Hempstead, UK) using a Thermo Hypersil GOLD column (Thermo Fisher Scientific, Runcorn, UK) (3 m, 50 ϫ 2.1 mm) and guard column (3 m, 10 ϫ 2.1 mm) with a run
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at ASPET Journals on June 20, 2017 dmd.aspetjournals.org time of 5 min, a flow rate of 0.45 ml/min, and column temperature of 50°C. Standard curves covering the concentration range of the samples and quality control samples, from a separate weighing of compound, were run with the samples. These were prepared by spiking the appropriate blank matrix (plasma, lung homogenate, or methanol) for measurement of plasma (and filter), lung, and dose solution samples. Lung standards were then extracted as described as for the lung samples. Appropriate dilutions of the lung samples were performed to ensure that detected levels were within the standard curve. The chromatographic method used was solvent mixture A (0.1% formic acid in methanol) and solvent mixture B (0.1% formic acid in water): 95% B was maintained for 0 to 0.5 min, followed by a linear gradient from 95% B to 0% B for 2.5 min, B was maintained at 0% until 3.6 min and increased to 95% between 3.5 and 3.6 min. The limit of quantitation was equivalent to 1 nM.
BAL Sample Analysis. The two BAL lavage tubes from each rat were centrifuged at 1800 rpm for 10 min at 4°C, and the lavage fluid supernatant from the first tube was retained and stored at Ϫ80°C for possible cytokine analysis. The lavage fluid supernatant from the second tube was discarded; the two cell pellets were combined and resuspended in 1 ml of Isoton and made up to a final volume of 5 ml. An aliquot of BAL fluid was removed and counted on the Sysmex XT2000Vet automated cell counter (Sysmex UK, Milton Keynes, UK). The results are expressed in cells per liter ϫ 10 9 . Cells were classified as eosinophils, neutrophils, or mononuclear cells (mononuclear cells included monocytes, macrophages, and lymphocytes) and were expressed as a percentage of the total cell count. TNF-␣ and IL-6 levels in the BAL supernatant were analyzed using DuoSets (DY510 and DY506; R&D Systems).
QSAR Model to Predict Lung/Plasma Partitioning. The statistical method used to generate the QSAR model was partial least squares (PLS) (Wold et al., 1987) using SIMCA-P software (Umetrics, Umeå, Sweden). The molecular structure of 34 compounds was used to calculate 195 two-dimensional and three-dimensional descriptors that broadly describe lipophilicity, hydrogen-bonding, size/shape, charge/polarity, topology, and drug ability of molecules. This descriptor calculation process was performed using an inhouse descriptor generator engine. These descriptors have been described in detail elsewhere (Katritzky et al., 1998; Bruneau, 2001) . From this original set of 195 descriptors, 41 were chosen (by selecting the most important descriptors in the variable importance plot generated as a result of the initial PLS model) to model the y data [measured log(lung/plasma partitioning)] for 34 compounds (training set). The number of components fitted was determined automatically in SIMCA-P using a leave many out procedure to assess their individual significance (leave 1/7 of the data points out, rebuilding the model 20 times). To test the robustness of the PLS model, a randomization test was performed 999 times (within SIMCA-P) on the initial observed y data.
The 41 descriptors for 34 compounds used to build the QSAR model are available in Supplemental Tables S1, S2 , S3, and S4 alongside the descriptors for the structures of compounds 1 to 9 (Supplemental Tables S5 and S6) and  their full chemical names (Supplemental Tables S7 and S8) . A temporal test set (test set 3) was used to test the performance of the QSAR model, providing a critical measure of the predictivity.
Data Analysis. Lung concentration and relationship to lung/plasma partitioning. Lung/plasma partitioning measured 6 h after an intratracheal dose was compared with measured lung concentrations at that time point (test sets 1 and 2). Linear regression was performed.
Pharmacodynamics and relationship to pharmacokinetics (exposure). The efficacious effect of a compound on BAL neutrophils, IL-6, and TNF-␣ in the rat LPS challenge model was expressed as mean percent inhibition of the mean response after administration of the vehicle control. Results between treatment groups were compared using nonparametric statistics (Mann-Whitney) to determine the level of significance of the effect. PKPD relationships were generated by comparing percent inhibition (yaxis) to the following measurements on the x-axis:
where rat % f u is the measured rat free fraction in plasma (percentage). These relationships were fitted, assuming a sigmoidal relationship, consistent with a classic PKPD relationship. Based on the observations for single compounds, a target ratio of the C min free lung concentration/rat AM IC 50 was selected as 4.
This value was consistent with achieving a minimum of 50% inhibition. Subsequent evaluation of multiple compounds provided a similar EC 50 ratio of 2.5 Ϯ 1.1 using a simple E max model approach. Therefore, it was reasonable to set a C min free lung concentration/rat AM IC 50 ratio of 4 for future compounds.
Measured lung dose in pharmacodynamic experiments. Lung doses were determined by comparing the plasma area under the curve (AUC) after inhalation to the exposure achieved after intravenous administration. Plasma AUC (0 -t) after inhalation dosing was determined using the trapezoidal method. AUC (0 -infinity) was estimated using the terminal half-life derived from intravenous dosing. The final lung dose was calculated from the following equation:
Lung dose ͑g/kg͒ ϭ ͑inhaled plasma AUC ⅐ 1000͒/͑i.v. plasma AUC @ 1000 g/kg͒ This method assumed complete absorption through the lung and negligible oral bioavailability. This assumption was confirmed for selected compounds after intratracheal, intravenous, and oral administration.
The lung doses were confirmed by two additional measurements as follows: 1) comparison of inhaled lung AUC with intratracheal lung AUC where the intratracheal dose was accurately known and 2) assumption of 10% of measured total inhaled dose. Total inhaled dose was calculated, as commonly described in the literature (Nerbrink et al., 1997) , as follows:
⅐ respiratory minute volume (ml/min) ⅐ exposure time (min) where chamber concentration (micrograms per liter) is equivalent to micrograms on filter/sampling volume.
Predicted lung dose. Predicted lung doses were derived using the following values: measured rat free fraction in plasma (rat %f u ), alveolar macrophage potency (rat AM IC 50 ), and predicted lung concentration. All predicted lung doses presented were generated for compounds that were not part of the original set used to derive the QSAR model for lung/plasma partitioning [23 compounds including structures referenced as compounds 1-9 (test set 3)].
Predicted lung/plasma partitioning (LP Split) was converted to a predicted lung concentration using the following equation:
Predicted lung concentration at 1000 g/kg ϭ 6.713 ⅐ LP Split ϩ 509.3 where 6.713 represents the slope and 509.3 represents the y-intercept of a plot of LP Split versus lung concentration. The ratio of free lung concentration relative to potency was determined for 1000 g/kg (x) as follows:
The lung dose required to achieve C min free lung concentration/cellular potency ϭ 4 was determined as follows:
Predicted lung dose ͑g/kg͒ ϭ 4 ⅐ 1000/X This target ratio was selected on the basis of the PKPD relationship of one compound and was used to predict efficacious lung doses for multiple new compounds that had not been tested in vivo. Thus, the doses predicted represented those required to achieve significant efficacy during the time course of the rat LPS model. The components to predict lung dose, as described above, can be combined into a single equation as follows:
Predicted efficacious lung dose ͑g/kg͒ ϭ 4 ⅐ 1000/͑͑͑6.713 ⅐ pred LP Split ϩ 509.3͒ ⅐ rat %f u /100͒/rat AM IC 50 ͒
Results
Pharmacokinetics. Figure 1 shows a representative profile of lung and plasma exposure after intratracheal and inhalation dosing. Because the number of rats used was two, it was not possible to determine the S.D. on these measurements. However, individual duplicates of lung concentration data are shown to indicate that the variability in measurements is low.
Terminal half-lives were independent of delivery route but were similar in plasma and lung. Partitioning between lung and plasma was similar irrespective of the method of delivery but varied from compound to compound. Similar partitioning was observed irrespective of whether it was measured a few minutes or several hours after dosing to the lung. Therefore, all measurements were collected 6 h after dosing to reflect the likely equilibrium condition and provide an estimate of minimal lung concentration required relevant to the time course of the rat LPS experiments. Figure 2 illustrates the correlation between lung/plasma partitioning and lung concentration for a given dose. Test set 1 gives a significant correlation ‫,ءءء(‬ p Ͻ 0.0001 and R 2 ϭ 0.97, where gradient ϭ 6.71 and intercept ϭ 509). This correlation was used to predict lung concentrations from the lung/plasma partition before lung doses are estimated. Subsequent measurements after intratracheal dosing showed a similar pattern, reinforcing the original correlation (test set 2).
Pharmacodynamics. Inhaled delivery resulted in a dose-related exposure in the lung and a good correlation between measured and predicted lung dose based on 10% of the total inhaled dose (data not shown). Dose-related inhibition of neutrophils, TNF-␣, and IL-6 in BAL was seen after inhalation administration of multiple individual compounds in the rat LPS model. Inhibition was shown to be in the range of Ͻ30% (nonsignificant) to ϳ80% (significant, ‫,ء‬ p Ͻ 0.05). These data were used to determine PKPD relationships by comparing responses to lung concentrations. PKPD Relationships. Efficacy, as indicated by inhibition of neutrophils, was related to lung concentrations for multiple compounds, shown in Fig. 3 (compounds A-H) . The lung dose required to achieve significant efficacy varied ϳ20-fold across the compound set (i.e., between ϳ5 and 100 g/kg). Figure 4 illustrates the PKPD relationships for the same compound set shown in Fig. 3 corrected for free fraction (derived from plasma protein binding measurements). In vitro cellular potency and minimal lung concentrations were taken into account. Similar patterns were obtained when other end points were evaluated (TNF-␣ and IL-6) (data not shown). These relationships were used to target free minimal lung concentrations of 4-fold over the in vitro potency for new compounds. This level of exposure relative to potency was expected to produce significant inhibition of 50% or greater as indicated in Fig. 4 . QSAR Model to Predict Lung/Plasma Partitioning. The QSAR model obtained for prediction of lung/plasma partition, based on the training set, is shown in Fig. 5 . The randomization test showed that no randomized case was statistically better than the initial model r 2 or q 2 (0.77 and 0.62, respectively), implying that the model is better than random. The quality of the models was measured using a range of statistics, providing guidance on how effectively a model fits the data and confidence in how the model would perform in making predictions. The root mean-square error (RMSE) of the training set is 0.41 log unit. A temporal test set (test set 3, compounds 1-9) was used to test the model's performance, providing a critical measure of the predictivity. The RMSE of the lung/plasma partition was found to be FIG. 2 . Correlation between lung/plasma partitioning measured 6 h after the intratracheal dose and the measured lung concentration at that time point. 
FIG. 3. Efficacy observed for multiple compounds (A-H) in the rat
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at ASPET Journals on June 20, 2017 dmd.aspetjournals.org 0.31 log unit. This value reflects the deviation of the predicted from the observed value for the temporal set. Thus, accurate predictions could be obtained from readily calculable descriptors. Key descriptors that were found to drive a high lung/plasma partition in this set of monobasic compounds were hydrogen bonding donor counts and polar surface area, whereas descriptors such as nonpolar surface area and fraction neutral were found correlate negatively. This is illustrated in Fig. 6 , which shows three representative structures and the impact of increasing hydrogen bond donor count, polar surface area, and/or reducing lipophilicity on lung/plasma partitioning.
Predicted Lung Doses. Predicted lung doses were generated for 23 compounds including test set 3 (compounds 1-9). None of these compounds were used to build the original QSAR model for lung/ plasma partitioning. Figure 7 shows the significant correlation (R 2 ϭ 0.7; ‫,ءءء‬ p Ͻ 0.0001) between predicted and actual efficacious lung doses for the 20 compounds with a measured in vivo dose. Compounds were predicted well, with 19 of 20 estimated within 3-fold, giving confidence that this approach could be used to aid decision making on testing in vivo. The structures and data on test set 3 (compounds 1-9) are shown in Fig. 8 and Table 1 and illustrate the variation in potency, free fraction, and predicted lung/plasma partition, which contribute to the overall predicted lung dose. Compounds 1 and 2 were not progressed in vivo as the dose prediction was so high. With allowance for some variation in the prediction, these compounds were highly unlikely to have acceptable inhaled lung doses. Compound 3 was considered borderline with a prediction of 88 g/kg and therefore worth progressing in vivo. This compound showed a trend toward efficacy (39% inhibition of neutrophils), although not quite reaching statistical significance in this experiment (72 g/kg). This result seemed to be consistent with the predicted lung dose (88 g/kg). The measured lung doses obtained for compounds 4 to 9 after in vivo testing were all within 2-to 3-fold of the predicted values, thus confirming the value of the model as a predictive tool.
Discussion
This work has demonstrated that is possible to develop PKPD relationships with concentrations measured in the target organ, in this case the lung. The relationships shown here seem to be classic in nature, based on a simple E max model (eq. 1):
where E max is maximal inhibition, C is the free concentration, and EC 50 is the free concentration to achieve 50% effect. Developing PKPD relationships in animal models after inhalation delivery is challenging for a number of reasons. First, the range of significant efficacy may be limited; in this case maximal inhibition was ϳ80%, and, on the basis of group size, the lowest statistically significant inhibition was in the region of ϳ30%.
Second, the route of delivery can introduce additional variability, and this is particularly true of inhalation, with which compounds can be delivered in solution, suspension, or as a dry powder. All of the compounds presented here were administered in solution, but earlier studies showed that compounds with poor aqueous solubility that were delivered as nebulized suspensions showed greater variability and generally weak or no efficacy for a given lung exposure (data not shown). This finding supported the hypothesis that calculated "free" lung concentrations of poorly soluble compounds may not always be in solution and available to the biological target, thus underestimating the concentration required to effectively drive a pharmacodynamic response. 
Downloaded from
For compounds delivered in solution, the intra-and interexperimental variation was similar to that which would be expected for this type of model. With regard to efficacy, it is not possible to express intraexperimental variability in terms of percent inhibition, because each animal cannot be its own control. However, it is possible to determine the variability in the cell numbers in lung sputum for a given regimen. As an example, compound 5 is representative of this variability with a coefficient of variation between 20 and 40% for the neutrophil cell count in BAL for a given regimen. With regard to interexperimental variability, a representative compound (compound C), studied on four separate occasions, produced a coefficient of variation of 15% for the inhibition of neutrophils and 29% for pharmacokinetic exposure (C max lung concentrations).
There is additional variability in measurements of in vitro properties, which can influence the ability to understand PKPD relationships. Naturally larger number of replicates can be measured in vitro and for representative compounds studied here, interexperimental coefficient of variation in potency and plasma binding measurements was Ͻ10%. Because of speed and cost constraints within a drug discovery setting, it is not feasible to produce multiple replicates of all of the parameters (e.g., free fraction, in vitro potency, lung concen- trations, and PD responses) for all compounds. Variability is a normal feature of biological systems and providing it is not excessive, it is possible to take a pragmatic approach and both develop meaningful PKPD relationships and compare the performance of different compounds on the basis of average data. There is a need to understand how pharmacological responses are driven by both compound concentrations and time. In this case, it was natural to attempt to link response to lung concentration, because the LPS challenge and compounds were delivered directly to the lung. The role of lung concentrations in driving efficacy was further supported by evidence that the PD response could be related to these concentrations, independent of the route of delivery (data not shown). The use of lung concentration data presents a challenge in itself, because individual animal measurements at single time points are required to attempt to build a PKPD relationship. If there is a temporal disconnect between exposure and response (creating a hysteresis phenomenon), it may be misleading to generate a PKPD relationship based on a single time point analysis. However, early studies on selected compounds, using a range of time points, did not show any evidence of hysteresis and indicated a relationship between lung concentrations and PD response at the same time point.
Incorporation of minimal free lung concentrations (C min ) and cellular potency into the PKPD relationships enabled the discovery of compounds with an appropriate balance of properties to achieve efficacy at a lung dose commensurate with successful development as a pharmaceutical product (e.g., Ͻ15 g/kg). When minimal free lung concentrations were in excess of the in vitro cellular IC 50 , significant inhibition of neutrophils was seen. A similar pattern was observed for other inflammatory endpoints (data not shown). This finding led to the possibility of using simple in vitro measurements and predicted lung exposure from the QSAR model to predict lung doses for future compounds. The prediction tool required a target ratio of C min free lung concentration to cellular potency, and this was derived from experience with a representative compound, which showed efficacy on multiple occasions. The data shown in Fig. 4 confirmed that targeting a ratio in excess of 4 was reasonable because these exposures achieved inhibition of neutrophils in excess of 50% for a range of other compounds.
Having established PKPD relationships and target exposures, it was possible to develop a prediction tool, taking into account the key in vitro parameters together with in silico predictions of lung concentrations. It is worth noting that additional error (above that generated from direct measurements discussed previously) can be introduced from the in silico QSAR model itself, which can influence the quality of any overall prediction. The error in the lung/plasma QSAR model presented here was determined and showed a similar RMSE in the training (0.41) and temporal (0.31) sets, demonstrating the good forward prediction capability of the model. For a wider context, the RMSE obtained compares well with errors in other recently published QSAR models, for example, human plasma binding (RMSE 0.4 -0.6) (Rodgers et al., 2007) , cytochrome P450 inhibition (RMSE 0.3-0.7) (Gleeson et al., 2007) , and brain tissue binding (RMSE 0.3-0.6) (Wan et al., 2007) . Additional investigation is required to determine whether it is possible to reduce RMSE further by using alternative approaches.
Lung doses were predicted well, with the majority of compounds being within 3-fold of their measured lung doses ( Fig. 7; Table 1 ). This is encouraging, given the recognized variability in the multiple components, which make up this prediction tool. This tool could be used to estimate lung doses, rank compounds, and discard the obvious poor candidates. Indeed this approach was used to make the decisions not to test compounds 1 and 2 in vivo but to progress compound 3. Table 1 illustrates the importance of balancing all of the relevant properties to achieve a low predicted lung dose. Compounds 1 and 2 had the weakest potency, and this clearly contributed to the high predicted lung doses. Compound 3 had good potency and high predicted lung concentrations but a low free fraction, leading to a relatively high predicted lung dose of 88 g/kg. This result suggested that a low free fraction can have a negative impact on the efficacious dose. Compound 4, with potency similar to that of compound 3, did have a higher free fraction but still predicted a high lung dose because it was predicted to have much lower lung concentrations relative to those of compound 3. Compounds 7 and 8 had differing potencies and predicted lung concentrations, which offset each other, leading to similar predicted lung doses. Compounds 8 and 9 are enantiomers (Fig. 8) and as a result have a similar free fraction and the same predicted lung/plasma partition. However, their potency does differ by 4-fold, which is possible, given the understanding of drug-protein interactions within the active site of this biological target. The impact of potency on the predicted and measured lung doses is also shown in Table 1 with the more potent compound 9 having the lowest lung dose. These examples (compounds 1-9) illustrate the need to balance properties to achieve the desired efficacy at an appropriate dose level. Compound 9 seems to have achieved this balance with high potency, reasonable free fraction, and lung partitioning, resulting in a predicted and measured lung dose of ϳ3 to 4 g/kg.
The implications of in silico predictions for lung/plasma partition and lung concentrations are profound, particularly because the QSAR model here was developed using compounds from diverse chemical series. These data provide medicinal chemists with an additional tool to drive better lung retention. The data generated suggest that lung concentrations can be modulated by Ͼ100-fold, offering the potential for significant reductions in efficacious dose. The most important molecular descriptors for driving a high lung/plasma partition are polarity terms such as polar surface area and hydrogen bond donor counts, which can be readily modulated in modern rational drug discovery projects. These findings indicate there are additional ways to optimize lung retention beyond lowering solubility and/or raising volumes of distribution.
In addition to providing a tool for prioritization of existing compounds in terms of progression into animal models, the in silico predictions were used extensively in compound design. The combination of a predicted lung/plasma partition along with a predicted free fraction and rat cell pIC 50 led to a prediction of an efficacious dose at the point of new compound conception, allowing effective prioritization for synthesis. The molecular descriptor directionality in the lung/plasma partition model was found to be broadly inverted with respect to the properties that drove a high predicted cellular potency. This learning led to the optimization of compounds into a narrow range of physicochemical properties, in which the balance between predicted lung retention and predicted cellular potency was optimal and hence compound attrition was minimized.
To our knowledge this is first time it has been possible to predict lung concentrations based on physical properties and apply them to estimate inhaled doses required for efficacy in an animal model. Because there are no comparisons to other work of this nature, it is unclear how good the level of performance of this prediction tool really is. Knowing the variability in biological systems and the multiple components required to estimate lung doses, predictions within 3-fold of the measured values would seem reasonable. Further work would be required to determine the true confidence intervals around these predictions. Nevertheless, it has been demonstrated that the current approach can provide sufficient confidence in the predictions to allow them to be used as a screening tool to aid in decision making. 
This work has demonstrated that it is possible to develop PKPD relationships after inhalation dosing and thus to understand the important factors driving efficacy in a well known animal model of inflammation. Through this understanding it has been possible to establish a method for estimating in vivo doses required for efficacy from simple in vitro measurements and in silico predictions of lung concentrations, thus providing a screening tool to decide whether a candidate compound merits further investigation. This approach revealed further insights into properties required for lung affinity, aiding compound design and allowed more rapid progression of promising compounds. The use of predicted rather than measured inhalation lung doses allowed effective decision making with the use of fewer animals.
